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Abstract
Background: Aminoglycoside antibiotic resistance is largely the
result of the production of enzymes that covalently modify the
drugs including kinases (APHs) with structural and functional
similarity to protein and lipid kinases. One of the most important
aminoglycoside resistance enzymes is AAC(6P)-APH(2Q), a bifunc-
tional enzyme with both aminoglycoside acetyltransferase and
kinase activities. Knowledge of enzyme active site structure is
important in deciphering the molecular mechanism of antibiotic
resistance and here we explored active site labeling techniques to
study AAC(6P)-APH(2Q) structure and function.
Results : AAC(6P)-APH(2Q) was irreversibly inactivated by
wortmannin, a potent phosphatidylinositol 3-kinase inhibitor,
through the covalent modification of a conserved lysine in the
ATP binding pocket. 5P-[p-(Fluorosulfonyl)benzoyl]adenosine, an
electrophilic ATP analogue and known inactivator of other APH
enzymes such as APH(3P)-IIIa, did not inactivate AAC(6P)-
APH(2Q), and reciprocally, wortmannin did not inactivate
APH(3P)-IIIa.
Conclusions: These distinct active site label sensitivities point to
important differences in aminoglycoside kinase active site struc-
tures and suggest that design of broad range, ATP binding site-
directed inhibitors against APHs will be difficult. Nonetheless,
given the sensitivity of APH enzymes to both protein and lipid
kinase inhibitors, potent lead inhibitors of this important
resistance enzyme are likely to be found among the libraries of
compounds directed against other pharmacologically important
kinases. ß 2001 Elsevier Science Ltd. All rights reserved.
Keywords: Antibiotic resistance; Aminoglycoside; Active site
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1. Introduction
Clinical resistance to aminoglycoside antibiotics is pri-
marily the result of enzymes that covalently modify the
antibiotics by N-acetylation, O-adenylation or O-phos-
phorylation. Aminoglycoside resistant strains of Gram-
positive pathogens such as Enterococcus, Staphylococcus
and Streptococcus commonly harbor plasmid-encoded ki-
nases that phosphorylate important hydroxyl groups on
the antibiotic (for review see [1]). The basis for resistance
lies in the fact that the phosphorylated aminoglycoside no
longer binds with high a⁄nity to its target, the aminoacyl
tRNA recognition site of the bacterial ribosome, thereby
rendering the antibiotic ine¡ective. The most studied and
best understood aminoglycoside kinase is APH(3P)-IIIa.
The structure of APH(3P)-IIIa is homologous to serine/
threonine kinases, despite very low amino acid sequence
similarity (6 10%) [2]. This three-dimensional similarity
parallels studies that have shown that aminoglycoside ki-
nases (APHs) can phosphorylate peptides and proteins on
Ser residues [3], and a growing body of evidence indicates
that the molecular mechanism of phosphoryl transfer is
similar in both classes of enzymes [4]. The structural and
functional homology between APH(3P)-IIIa and protein
kinases, and by inference all of the APHs, prompted a
screen of protein kinase inhibitors to identify potential
leads in the design of inhibitors against the aminoglycoside
resistance enzymes. Indeed, several protein kinase inhibi-
tors were identi¢ed for APH(3P)-IIIa and another impor-
tant aminoglycoside kinase, AAC(6P)-APH(2Q) [5].
AAC(6P)-APH(2Q) is a bifunctional enzyme incorporat-
ing an N-terminal aminoglycoside acetyltransferase do-
main (AAC) and a C-terminal aminoglycoside kinase do-
main, and is responsible for the majority of clinically
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relevant aminoglycoside resistance in Gram-positive bac-
teria [6].
Although protein kinase inhibitors were identi¢ed for
both APHs tested, the two enzymes showed de¢nite selec-
tivity towards speci¢c compounds [5] indicating that the
kinase active sites have important geometrical di¡erences.
This is consistent with the fact that the enzymes also have
di¡erent aminoglycoside substrate pro¢les [7,8], with the
kinase domain of AAC(6P)-APH(2Q) (referred to as
APH(2Q)-Ia herein) having a broader substrate speci¢city
than APH(3P)-IIIa; an observation that implies that
APH(2Q)-Ia has a greater ability to accept more diverse
structures into its active site. In addition to a broader
aminoglycoside speci¢city, APH(2Q)-Ia has a more expan-
sive kinase regiospeci¢city with the capacity to phosphor-
ylate a number of hydroxyl groups around the aminogly-
coside core, including positions 3P, 5Q, 2Q and 3QP
depending on the aminoglycoside [8,9]. APH(3P)-IIIa, in
contrast, phosphorylates either 3P- and/or 5Q-hydroxyls
[7,10] (Fig. 1). The kinetic mechanisms of the two enzymes
are also di¡erent: APH(3P)-IIIa follows a Theorell^
Chance mechanism where ADP release is solely rate limit-
ing [11,12], while APH(2Q)-Ia proceeds through a random
rapid equilibrium mechanism [13] with the catalytic step
making an important contribution to the turnover rate
(Boehr and Wright, unpublished observations).
Fig. 1. Regiospeci¢cities of phosphoryl transfer by APH(3P)-IIIa and APH(2Q)-Ia, the phosphotransferase domain of AAC(6P)-APH(2Q). APH(3P)-IIIa
catalyzes phosphoryl transfer onto 4,6-disubstituted aminoglycosides exclusively on 3P-OHs, whereas it can bisphosphorylate 3P-OHs and 5P-OHs on 4,5-
disubstituted aminoglycosides [7,10]. Phosphorylation by APH(2Q)-Ia is highly dependent upon the individual aminoglycoside, where the enzyme can
phosphorylate similar and di¡erent sites than APH(3P)-IIIa [8,9].
Fig. 2. Structure and reactivity of kinase active site labeling compounds FSBA (A) and wortmannin (B). A nucleophile in the active site, generally a ly-
sine, attacks the electrophilic position on the respective compound as indicated resulting in an inactivated enzyme.
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The rational design of selective inhibitors of aminogly-
coside kinases requires a structural understanding of the
di¡erences between these enzymes, however while much
information has been gleaned from the structural determi-
nation of APH(3P)-IIIa, similar information is lacking for
APH(2Q)-Ia. As a ¢rst step in elaborating the structural
di¡erences between these enzymes, we elected to explore
active site labeling techniques.
One candidate active site label is the electrophilic ATP
analogue 5P-[p-(£uorosulfonyl)benzoyl]adenosine (FSBA),
which was previously shown to inactivate APH(3P)-IIIa
by modifying the invariant Lys44 in the ATP binding
pocket [14]. Another candidate is the lipid kinase inhibitor
wortmannin (see Fig. 2 for structures). Lipid kinases also
share a similar fold with aminoglycoside and protein ki-
nases, as seen with the three-dimensional structure of
phosphatidylinositol phosphate kinase type IIB [15], and
therefore, lipid kinase inhibitors have the potential to
inhibit aminoglycoside kinases as well. Wortmannin was
originally discovered to be an inhibitor of myosin light
chain kinase with an IC50V0.2 WM [16]. Later studies
showed wortmannin to be a 100-fold more potent irrevers-
ible inhibitor of phosphatidylinositol 3-kinase (PI 3-ki-
nase) with an IC50V2 nM [17], and is now commonly
used to study the role of PI 3-kinase in signal transduction
cascades (for review see [18]). Wortmannin acts by cova-
lently binding Lys802 in the ATP binding pocket of PI
3-kinase [19]. A study of a series of structural analogues
of wortmannin concluded that PI 3-kinase is irreversibly
inactivated through nucleophilic attack of the Lys amino
group at the C21 position of wortmannin generating the
substituted K^L unsaturated lactone (Fig. 2) [20].
In the present study, we show that wortmannin is an
inactivator of APH(2Q)-Ia but not APH(3P)-IIIa. This con-
trasts with the ATP analogue FSBA which did not inacti-
vate APH(2Q)-Ia, but was previously shown to covalently
modify APH(3P)-IIIa and the spectinomycin kinase
APH(9)-Ia [14,21]. These di¡erent active site labeling sen-
sitivities provide a chemical means of discriminating be-
tween aminoglycoside kinases and highlight the geometri-
cal di¡erences in the active sites of the two enzymes.
2. Results
2.1. Kinetic analysis of APH(2Q)-Ia domain and N-terminal
6-histidine (6-His)-tagged AAC(6P)-APH(2Q)
We have previously reported the puri¢cation of the ami-
noglycoside resistance determinant AAC(6P)-APH(2Q) in
Bacillus subtilis using an expression plasmid under the
control of the constitutive vegII promoter [8]. In this
study, we created Escherichia coli expression constructs
that introduce an N-terminal hexa His tag on AAC(6P)-
APH(2Q) (HisAAC(6P)-APH(2Q)) for ease in puri¢cation
and a construct that expresses a C-terminal truncated ver- Ta
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sion that encodes only the APH(2Q)-Ia domain of the bi-
functional enzyme (Fig. 3).
The N-terminal His tag did not have a signi¢cant e¡ect
on the activity of AAC(6P)-APH(2Q). Although there were
modest changes to KM and kcat for some substrates, the
catalytic e⁄ciencies (kcat/KM) for these substrates re-
mained comparable to those determined for the B. subti-
lis-expressed enzyme (Table 1). Likewise, the C-terminal
truncated version encoding only the APH(2Q) domain did
not display signi¢cantly di¡erent aminoglycoside modi¢-
cation properties (Table 1).
Most of the subsequent studies utilized the C-terminal
truncated version of APH(2Q), except where indicated. The
B. subtilis-expressed AAC(6P)-APH(2Q), HisAAC(6P)-
APH(2Q) and the truncated APH(2Q)-Ia domain all showed
identical sensitivities to the active site labeling compounds
FSBA and wortmannin (data not shown).
2.2. APH(2Q)-Ia and APH(3P)-IIIa have di¡erent
sensitivities to the covalent modi¢ers FSBA and
wortmannin
FSBA, an inactivator of APH(3P)-IIIa [14], did not have
an e¡ect on either the acetyltransferase or phosphotrans-
ferase activity of HisAAC(6P)-APH(2Q) at concentrations
of 2 mM (data not shown). In contrast, wortmannin did
not a¡ect the activity of APH(3P)-IIIa up to a concentra-
tion of 2 mM, but did e⁄ciently inactivate the phospho-
transferase domain of HisAAC(6P)-APH(2Q) (Fig. 4). The
reaction appeared to be irreversible as extensive dialysis or
gel ¢ltration could not restore APH activity. The acetyl-
transferase activity of the bifunctional enzyme was not
a¡ected (Fig. 4). Thus, FSBA is a speci¢c inactivator of
APH(3P)-IIIa, whereas wortmannin is speci¢c to APH(2Q)-
Ia.
Wortmannin inactivation of APH(2Q) was accompanied
by a marked change in color of the reaction mixture from
colorless to yellow, which permitted ready monitoring of
enzyme inactivation by monitoring of the increase in ab-
sorbance at 440 nm (Fig. 5). The presence of an isosbestic
point is consistent with formation of a single wortmannin
species.
Fig. 3. Purity of APH(2Q) enzymes. The sodium dodecyl sulfate^poly-
acrylamide gel was stained with Coomassie blue. Lane 1, molecular
mass standards; lane 2, APH(2Q)-Ia fragment beginning at Met175 of
AAC(6P)-APH(2Q) ; lane 3, His6-AAC(6P)-APH(2Q).
Fig. 4. Wortmannin inactivates the aminoglycoside kinase (APH(2Q)) ac-
tivity of AAC(6P)-APH(2Q). Inactivation assays were performed as de-
scribed in Section 5 following a 60 min incubation at 22‡C.
Fig. 5. Reaction of wortmannin with HisAAC(6P)-APH(2Q) as followed
by absorbance spectrum scans with a Cary 3E UV/Vis spectrophotome-
ter.
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2.3. ATP protection of APH(2Q)-Ia activity from
inactivation by wortmannin
To validate the speci¢city of the reaction and to localize
the site of modi¢cation, substrate protection experiments
were performed. Neither kanamycin A nor acetyl CoA
a¡orded any protection to APH(2Q)-Ia, however, ATP
was able to protect APH(2Q)-Ia from inactivation (Fig.
4), suggesting that wortmannin binds at or near the ATP
binding pocket of APH(2Q)-Ia and interacts with an im-
portant active site residue.
2.4. Kinetics of inactivation of APH(2Q)-Ia by wortmannin
Wortmannin inactivated APH(2Q)-Ia in both a concen-
tration- and time-dependent manner following pseudo ¢rst
order kinetics (Fig. 6A), consistent with the following
model:
E IK i EIÿ!kmax EI
where Ki is the apparent binding constant, kmax is the rate
of inactivation at saturating inactivator (I), and EI* is the
modi¢ed enzyme. Replot of the pseudo ¢rst order con-
stants, kobs, versus wortmannin concentration to deter-
mine Ki and kmax revealed the predicted saturation kinetics
typical of enzyme a⁄nity reagents (Fig. 6B). The dissoci-
ation constant, Ki, and the maximal rate of inactivation,
kmax, were calculated to be 1.05 þ 0.1 mM and 1.51 þ
0.07U1032 min31 respectively. Thus wortmannin was
shown to be a speci¢c inactivator of APH(2Q)-Ia likely
functioning by covalently labeling the enzyme in a region
adjacent or overlapping the ATP binding site.
Fig. 6. Time- and concentration-dependent inactivation of APH(2Q)-Ia
by wortmannin. (A) APH(2Q)-Ia (0.4 nmol) in 50 mM HEPES-NaOH
pH 7.5 and DMSO (5% v/v) inactivated with wortmannin at a ¢nal
concentration of 100 (a), 200 (b), 500 (E), 1000 (F) and 2000 (O) WM.
(B) Plot of ¢rst order rates of inactivation (kobs) vs. inactivator concen-
tration. The inset is a double reciprocal replot to determine Ki and
kmax, which were calculated to be 1.05 þ 0.1 mM and 1.51 þ 0.07U1032
min31 respectively.
Table 2
Peptides labeled by wortmannin as identi¢ed by mass spectral analysis
of trypsin-digested and inactivated APH(2Q)-Ia
Peptide Predicted modi¢ed residue
YDDNATVK*AMK Lys13
LVNNEYIFK*TK Lys52
STMSEEEQNLLK*R Lys125
NIK*QEFIENGR Lys287
Table 3
Kinetic analysis of APH(2Q)-Ia Lys to Ala mutants
KM (WM) kcat (s31) kcat/KM (M31 s31) kcat (WT)/kcat (mut) kcat/KM (WT)/kcat/KM (mut)
Lys13Ala
Kanamycin Aa 10.6 þ 2.0 0.28 þ 0.02 2.6U104 0.86 1.5
ATPb 113 þ 12 0.33 þ 0.02 2.9U103 0.64 0.79
Lys52Ala
Kanamycin Ac 2.07 þ 0.86 0.017 þ 0.001 8.2U103 14 4.9
ATPb 227 þ 36 0.015 þ 0.001 6.6U101 14 35
Lys125Ala
Kanamycin Aa 6.53 þ 1.13 0.20 þ 0.01 3.1U104 1.2 1.3
ATPb 100 þ 12 0.24 þ 0.02 2.4U103 0.88 0.96
Lys287Ala
Kanamycin Aa 8.80 þ 1.03 0.30 þ 0.01 3.4U104 0.80 1.2
ATPb 94 þ 13 0.23 þ 0.02 2.4U103 0.88 0.96
aATP held at 1 mM.
bKanamycin A held at 100 WM.
cATP held at 2 mM.
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2.5. Wortmannin labels Lys residues in APH(2Q)-Ia
Identi¢cation of covalently labeled amino acids was ac-
complished using a combination of tryptic peptide map-
ping and mass spectral analysis. Four Lys residues (Lys13,
Lys52, Lys125 and Lys287) were tentatively identi¢ed as
being modi¢ed under the conditions used to perform the
experiment (Table 2). E¡orts to establish stoichiometry of
labeling using mass spectrometry (MS) failed.
The role of each of the identi¢ed Lys residues in the
aminoglycoside modifying activity of APH(2Q)-Ia was
probed by mutating each Lys to Ala separately and char-
acterizing the mutant enzymes. Mutagenesis of Lys13,
Lys125 and Lys287 had little to no e¡ect on the activity
of APH(2Q)-Ia (Table 3). However, mutagenesis of Lys52
had a dramatic e¡ect on the aminoglycoside modifying
ability of APH(2Q)-Ia with signi¢cant changes on both
the ATP and kanamycin A kinetic parameters (Table 3).
The e¡ect was most pronounced with respect to ATP
where there was a 35-fold decrease in the catalytic e⁄-
ciency (Table 3) which is consistent with this residue hav-
ing a role in ATP capture, and demonstrates that this
residue is homologous to Lys44 in APH(3P)-IIIa as sug-
gested by the primary sequence alignment (Fig. 7). An
equivalent Lys44Ala mutation in APH(3P)-IIIa had a sim-
ilar 31-fold e¡ect on catalytic e⁄ciency [23].
The impact of mutating Lys52 on ATP capture is con-
sistent with the conclusion that wortmannin inactivates
APH(2Q)-Ia by covalently modifying this residue. Addi-
tional support for this conclusion comes from the obser-
vation that wortmannin did not e⁄ciently inactivate the
Lys52Ala mutant (s 90% activity remaining) under con-
ditions where the wild type enzyme was completely inacti-
vated (6 1% activity remaining) (Fig. 8). The other Lys
mutants remained susceptible to wortmannin inactivation
(Fig. 8).
3. Discussion
AAC(6P)-APH(2Q) and APH(3P)-IIIa are major amino-
glycoside antibiotic resistance determinants in Gram-pos-
itive pathogens such as Enterococcus and Staphylococcus
(for review see [22]). The two enzymes share a common
active site motif, which is similar to that of protein and
lipid kinases. The structure of APH(3P)-IIIa con¢rmed the
similarity with protein and lipid kinases [23], and further
functional studies showed that both AAC(6P)-APH(2Q)
and APH(3P)-IIIa have serine protein kinase activity [3]
and are sensitive to protein kinase inhibitors [5]. Although
the phosphotransferase domain of the bifunctional enzyme
is likely to be structurally homologous to APH(3P)-IIIa,
APH(3P)-IIIa and APH(2Q)-Ia have important functional
di¡erences, including di¡erent aminoglycoside substrate
speci¢cities [7,8], phosphoryl transfer regiospeci¢cities [7^
10], kinetic mechanisms [11^13], and inhibitor sensitivities
[5]. The structure of APH(3P)-IIIa has provided much
valuable information that has directed our search for in-
hibitors of aminoglycoside kinases, but considering the
important di¡erences with APH(2Q)-Ia, we also sought
structural information concerning this important amino-
glycoside resistance determinant.
3.1. Inactivation of AAC(6P)-APH(2Q) with wortmannin
FSBA had previously been shown to inactivate
APH(3P)-IIIa by covalently modifying a conserved lysine
Fig. 7. Primary sequence alignment of aminoglycoside phosphotransferases. Lysines modi¢ed in APH(2Q)-Ia by wortmannin are highlighted. Only Lys52
is conserved among the APHs (highlighted in blue) and is homologous to Lys44 in APH(3P)-IIIa which is known to interact with the K- and L-phos-
phates of ATP.
Fig. 8. Wortmannin inactivation of LysCAla mutants of APH(2Q)-Ia.
Only the Lys52Ala mutant is protected against inactivation.
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that is important in binding ATP [14], but this compound
had no e¡ect on APH(2Q)-Ia. In contrast, wortmannin, a
potent PI 3-kinase inactivator, was able to inhibit
APH(2Q)-Ia but had no e¡ect on APH(3P)-IIIa. Peptide
mapping of APH(2Q)-Ia following inactivation by wort-
mannin under saturating conditions and after prolonged
incubation identi¢ed four candidate peptides containing
Lys residues, which have the potential to react with the
compound. Mutagenesis of only Lys52 substantially al-
tered the aminoglycoside modifying ability of APH(2Q)-Ia
and wortmannin did not inactivate the Lys52Ala mutant
but was still able to inactivate the other Lys to Ala mu-
tants, demonstrating that wortmannin inactivation of
APH(2Q)-Ia requires Lys52 but not the other lysines iden-
ti¢ed in the mapping experiment. ATP protection of
APH(2Q)-Ia is consistent with modi¢cation of Lys52,
where primary sequence alignment has shown this residue
to be homologous to Lys44 in APH(3P)-IIIa (Fig. 7), a
residue known to interact with the K- and L-phosphates
of ATP [23]. We conclude that wortmannin inactivates
APH(2Q)-Ia by covalently modifying Lys52 in the ATP
binding pocket. This conclusion is consistent with experi-
ments on PI 3-kinase where wortmannin was shown to
inactivate this lipid kinase by covalent modi¢cation of
Lys802 [19], a residue homologous to Lys52 and Lys44
in APH(2Q)-Ia and APH(3P)-IIIa respectively. Modi¢cation
of the three other lysines in APH(2Q)-Ia was likely an
artifact of the prolonged incubation conditions used and
to the non-speci¢c reactivity of this electrophilic com-
pound.
3.2. Di¡erences in the ATP binding pockets of
aminoglycoside phosphotransferases and
implications for inhibitor design
It is intriguing that FSBA and wortmannin modify the
homologous residue in the aminoglycoside phosphotrans-
ferases, and yet FSBA is speci¢c for APH(3P)-IIIa and
wortmannin is speci¢c for APH(2Q)-Ia. This suggests that
there are fundamental di¡erences in the ATP binding
pockets of these two enzymes, in agreement with our pre-
vious studies showing that the enzymes have di¡erent sen-
sitivities to certain protein kinase inhibitors which are gen-
erally targeted towards the ATP binding pocket [5]. Even
among very similar protein kinases, there are di¡erences in
inhibitor sensitivities, and many potent and speci¢c inhib-
itors have been directed against the ATP binding pocket
of important pharmacological targets (reviewed in [24]).
However, in the case of aminoglycoside kinases, it would
be more desirable to develop broad range inhibitors that
could inhibit a number of enzymes. The results of this
study suggest that it would be challenging to develop
broad range and potent inhibitors of aminoglycoside ki-
nases by directing compounds against the ATP binding
pocket. A broad range inhibitor would likely need to
take advantage of other features common to the APHs
such as the aminoglycoside binding pocket, but even
then, design would be di⁄cult considering that APHs
show a diverse range of aminoglycoside substrate pro¢les
and regiospeci¢cities.
More potent and speci¢c inactivators of APH(2Q)-Ia
based on the wortmannin structure would likely require
modi¢cations around the C and D rings, as studies
with PI 3-kinase have identi¢ed these rings as critical
in initial binding e⁄ciency [20,25]. In the case of
APH(2Q)-Ia, positively charged substitutions might be fa-
vored as a negatively charged active site is a common
motif in the structures of aminoglycoside modifying en-
zymes [23,26^28].
4. Signi¢cance
The most clinically relevant mode of resistance to ami-
noglycosides is the enzymatic modi¢cation of these anti-
biotics. A structural understanding of the resistance en-
zymes will aid in the development of potent inhibitors,
where active site labeling techniques provide a means of
identifying important enzymatic residues. Wortmannin, a
potent PI 3-kinase inhibitor, inactivates the phosphotrans-
ferase domain of AAC(6P)-APH(2Q) (APH(2Q)-Ia) by cova-
lently modifying an absolutely conserved lysine in the ATP
binding pocket, however, it does not inactivate APH(3P)-
IIIa. Likewise, FSBA, an electrophilic ATP analogue in-
activates APH(3P)-IIIa but does not a¡ect APH(2Q)-Ia
activity, suggesting that the APHs have important di¡er-
ences in their ATP binding pockets. Considering these
di¡erences, the design of broad range inhibitors against
APHs will require interactions with other sites common
to APHs, such as the aminoglycoside binding pocket.
Wortmannin inactivation of APH(2Q)-Ia complements oth-
er functional and structural studies demonstrating that
protein, lipid and aminoglycoside kinases all share a com-
mon structural motif and suggests that these classes of
enzymes all have a common ancestor. This ¢nding augurs
well for the discovery of APH inhibitors among the libra-
ries of compounds developed for other pharmacologically
important kinases.
5. Materials and methods
5.1. Chemicals
ATP, acetyl CoA, dithiodipyridine, L-NADH, phosphoenol py-
ruvate, pyruvate kinase/lactate dehydrogenase enzymes, and
wortmannin were from Sigma (St. Louis, MO, USA). Kanamycin
A, gentamicin and IPTG (isopropyl-L-D-thiogalactopyranoside)
were from Bioshop (Burlington, ON, Canada). Restriction endo-
nucleases were from MBI Fermentas (Hamilton, ON, Canada).
All oligonucleotide primers were synthesized at the Central Fa-
cility of the Institute for Molecular Biology and Biotechnology,
McMaster University.
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5.2. Subcloning of aph(2Q)-Ia into pET22b(+) and
aac(6P)-aph(2Q) into pET15b(+)
Plasmid pETBFAPH was constructed by the ligation of a 1 kb
aph(2Q)-Ia fragment of the bifunctional aac(6P)-aph(2Q) gene be-
ginning at position 525 of the gene, corresponding to Met175 (D.
Daigle and G. Wright, unpublished) digested with NdeI and Hin-
dIII into pET22b(+), and likewise, plasmid pET15AACAPH was
constructed by the ligation of the 1.5 kb aac(6P)-aph(2Q) insert
from pBF9 [8] digested with NdeI and BamHI into pET15b(+),
which generates the N-terminal 6-His-tagged enzyme. The new
constructs were transformed into CaCl2-competent E. coli
BL21(DE3) for subsequent overexpression and puri¢cation.
5.3. Puri¢cation of enzymes
APH(3P)-IIIa was puri¢ed by previously described methods [7].
Overexpression of APH(2Q)-Ia and the N-terminal His-tagged
AAC(6P)-APH(2Q) was similar to that for APH(3P)-IIIa, where 1 l
of Luria broth supplemented with 50 Wg/ml kanamycin A was
inoculated with 10 ml of an overnight culture of E. coli
BL21(DE3) containing the appropriate constructs and grown at
37‡C for 3 h until OD600V0.6. Enzyme production was induced
by the addition of 1 mM IPTG and grown for a further 3 h at
37‡C. The cells were collected by centrifugation at 5000Ug for
10 min, resuspended and washed with 0.85% NaCl, before storing
them overnight at 320‡C.
The puri¢cation of APH(2Q)-Ia followed the same procedure as
that used to purify the full length, non-His-tagged enzyme as
outlined in [8]. For the puri¢cation of the N-terminal His-tagged
version of AAC(6P)-APH(2Q), the cells were resuspended in 15 ml
50 mM Na2HPO4 pH 8.0, 300 mM NaCl, 10 mM imidazole,
lysed using a French pressure cell at 20 000 psi and the super-
natant cleared by centrifugation (10 000Ug for 20 min). The 15 ml
of crude lysate was gently mixed with 5 ml Ni NTA agarose for
1 h at 4‡C, and then loaded onto a column (9U3 cm). The resin
was washed with 20 ml 50 mM Na2HPO4 pH 8.0, 300 mM NaCl,
20 mM imidazole and 20 ml 50 mM Na2HPO4 pH 8.0, 300 mM
NaCl, 40 mM imidazole. The protein was eluted with 25 ml
50 mM Na2HPO4 pH 8.0, 300 mM NaCl, 250 mM imidazole.
The fractions containing puri¢ed AAC(6P)-APH(2Q) were pooled,
concentrated over an Amicon PM30 membrane and dialyzed
against 50 mM HEPES pH 7.5, 1 mM EDTA. Approximately
50 mg of His-tagged AAC(6P)-APH(2Q) was puri¢ed from a 1 l
cell culture.
Protein concentrations were determined using the Bradford
method [29].
5.4. APH and AAC kinetic assays
The assays used to measure aminoglycoside phosphotransfer-
ase and acetyltransferase activities were previously described in
[8]. However, most assays were scaled down from 1 ml to 250 Wl
volumes, so they could be conducted in 96 well microtiter plates
using a Molecular Devices SpectraMax Plus microtiter plate read-
er.
For Michaelis^Menten kinetic determinations, initial rates were
¢t by non-linear least squares to Eq. 1, using Gra¢t version 4.0
[30].
v  kcat=EtS=Km  S 1
5.5. Inactivation of AAC(6P)-APH(2Q) by wortmannin
Wortmannin inactivation experiments were conducted in
50 mM HEPES-NaOH pH 7.5 at room temperature with various
concentrations of wortmannin dissolved in dimethyl sulfoxide
(DMSO; 5% v/v for all wortmannin concentrations including
controls) in a total volume of 20 Wl. Reactions were initiated by
the addition of enzyme (0.3^0.5 nmol) and 5 Wl aliquots were
removed, added to 37‡C temperature-equilibrated assay broth
and assayed for kanamycin kinase or acetyltransferase activ-
ity.
5.6. Large scale a⁄nity labeling of APH(2Q)-Ia to determine the
site(s) of modi¢cation
APH(2Q)-Ia (100 nmol) was inactivated by the addition of sev-
eral aliquots of wortmannin (1 Wmol every 2 h for a total of 6 h)
to the inactivation bu¡er consisting of 50 mM HEPES-NaOH pH
7.5 and 10 mM MgCl2 in a total volume of 0.5 ml. The control
incubation, without wortmannin but with an equivalent amount
of DMSO, was carried out simultaneously. Inactivation was
deemed complete when 6 2% of the kanamycin phosphotransfer-
ase activity remained.
The volume of the reactions was increased to 1.5 ml, and the
solutions were dialyzed against 2 l 25 mM NH4HCO3 pH 8.3 at
4‡C. One volume of 200 mM Tris^HCl pH 8.3, 2 mM EDTA,
8 M urea and 4 mM dithiothreitol was then added and the solu-
tions stirred for 1 h under nitrogen at room temperature. To cap
cysteine residues, 1.1 equivalents iodoacetic acid per cysteine res-
idue (550 nmol) were added to the reaction mixture and stirred
for an additional 60 min in the dark. The reactions were subse-
quently dialyzed overnight against 20 mM NH4HCO3 pH 8.3 at
4‡C. The solutions were then evaporated using a SpeedVac, be-
fore resuspension in 100 Wl 100 mM NH4HCO3 pH 8.3, 8 M
urea. The reactions were incubated at room temperature for
30 min prior to the addition of 45.5 Wl 100 mM NH4HCO3 pH
8.3 and 5.5 Wl of trypsin solution (2 mg trypsin in 50 ml 1.2 M
HCl). The trypsin digestion was allowed to proceed for 24 h at
room temperature in the dark before freezing and storing the
reactions at 380‡C.
Table 4
Oligonucleotide primers used in this study to generate appropriate APH(2Q)-Ia mutants
Mutant Mutagenic primer (5P to 3P)
Lys13Ala GCCACAAATGTTGCGGCAATGAAATATTTAATTGAGC
Lys52Ala GGCATATTTAGTTAATAATGAATACATTTTTGCAACAAAATTTAG
Lys125Ala GTCAGAAGAAGAACAAAATTTGTTAGCACGAGATATTGCC
Lys287Ala GGAATTAAAAATATTGCACAGGAATTTATCGAAAATGGTAGAAAAG
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5.7. Trypsin digest analysis
Multiple peptide sequences were determined in a single run by
microcapillary reverse-phase chromatography directly coupled to
a Finnigan LCQ quadrupole ion trap mass spectrometer
equipped with a custom nanoelectrospray source. The column
was packed in-house with 10 cm of POROS 10R2 into a New
Objective one-piece 75 Wm in diameter column terminating in an
8.5 Wm tip. Flow rate was nominally 200 nl/min. The ion trap
repetitively surveyed MS (395^1400 m/z), executing data-depen-
dent scans on the three most abundant ions in the survey scan,
allowing high resolution (zoom) scans to determine charge state
and exact mass, and MS/MS spectra for peptide sequence infor-
mation. MS/MS spectra were acquired with a relative collision
energy of 30% and an isolation width of 2.5 Da. Recurring ions
were dynamically excluded. After database correlation with SE-
QUEST, modi¢ed peptides were con¢rmed by manual interpre-
tation of the MS/MS spectra using FuzzyIons [31,32].
5.8. Site-directed mutagenesis of selected lysine residues to alanine
Peptide mapping results identi¢ed four potential Lys residues
that were being modi¢ed by wortmannin. To determine the role
of each Lys in the activity of APH(2Q)-Ia, they were individually
mutated to Ala using the Quik-Change mutagenesis method
(Stratagene, La Jolla, CA, USA). Brie£y, the appropriate muta-
genic oligonucleotides (Table 4) and their reverse complements
were used in combination with 10 ng template DNA (pETB-
FAPH) in Pfu DNA polymerase (Stratagene, La Jolla, CA,
USA)-catalyzed PCR reactions. Parental DNA was digested
with DpnI, before the mutant plasmid DNA was transformed
into CaCl2-competent E. coli XL1-Blue. Positive clones were se-
quenced in their entirety before transformation into E. coli
BL21(DE3) and subsequent protein puri¢cation.
5.9. Absorbance spectrum of HisAAC(6P)-APH(2Q) inactivated
with wortmannin
The course of the reaction between HisAAC(6P)-APH(2Q) (17
nmol) and wortmannin (250 nmol) in 0.5 ml 50 mM HEPES-
NaOH pH 7.5 at room temperature was followed by taking ab-
sorbance scans from 200 nm to 600 nm every 10 min using a Cary
3E UV/Vis spectrophotometer.
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